Lipids and lipoproteins during treatment
| Week | |||||
|---|---|---|---|---|---|
| Variable | Treatment | 0 | 24 | 48 | p Value* |
| Sample size† | Placebo | 27 | 22 | 21 | |
| Losartan | 26 | 23 | 21 | ||
| Spironolactone | 27 | 20 | 17 | ||
| Total cholesterol, mg/dL | Placebo | 189 (49) | 187 (40) | 189 (54) | 0.06 |
| Losartan | 198 (75) | 179 (54) | 179 (53) | ||
| Spironolactone | 176 (44) | 185 (56) | 173 (42) | ||
| LDL cholesterol, mg/dL | Placebo | 95 (38) | 96 (32) | 97 (38) | 0.40 |
| Losartan | 100 (45) | 92 (39) | 93 (47) | ||
| Spironolactone | 75 (29) | 82 (38) | 76 (31) | ||
| HDL cholesterol, mg/dL | Placebo | 43 (10) | 47 (14) | 42 (13) | 0.12 |
| Losartan | 46 (15) | 42 (13) | 43 (12) | ||
| Spironolactone | 45 (11) | 40 (11) | 41 (10) | ||
| Triglycerides, mg/dL | Placebo | 183 (145 to 232) | 178 (146 to 217) | 192 (148 to 249) | <0.01 |
| Losartan | 175 (136 to 225) | 170 (128 to 227) | 150 (116 to 194) | ||
| Spironolactone | 191 (156 to 235) | 241 (172 to 339) | 219 (162 to 294) | ||
| Triglycerides/HDL | Placebo | 4.3 (3.3 to 5.7) | 4.0 (3.0 to 5.3) | 4.7 (3.3 to 6.7) | <0.01 |
| Losartan | 4.0 (2.9 to 5.6) | 4.2 (2.9 to 6.1) | 3.6 (2.6 to 5.1) | ||
| Spironolactone | 4.3 (3.4 to 5.5) | 6.2 (4.1 to 9.4) | 5.5 (3.8 to 8.0) | ||
| VLDL+IDL-C, mg/dL | Placebo | 41.8 (32.3 to 54.2) | 38.9 (30.7 to 49.4) | 40.3 (29.9 to 54.2) | <0.01 |
| Losartan | 40.0 (30.7 to 52.1) | 35.8 (26.4 to 48.7) | 35.7 (27.5 to 46.3) | ||
| Spironolactone | 47.3 (38.2 to 58.6) | 50.3 (36.2 to 69.7) | 46.5 (33.6 to 64.2) | ||
| VLDL+IDL Apo-B, mg/dL | Placebo | 31.3 (24.4 to 40.2) | 28.4 (22.7 to 35.5) | 30.1 (23.0 to 39.5) | <0.01 |
| Losartan | 28.3 (22.8 to 35.2) | 25.3 (19.6 to 32.8) | 26.7 (21.0 to 33.8) | ||
| Spironolactone | 33.5 (28.0 to 40.1) | 34.2 (26.8 to 43.5) | 33.3 (25.2 to 44.0) | ||
Data are presented as mean (SD) or geometric mean (95% CI).
Apo-B, apolipoprotein B; HDL, high-density lipoprotein; IDL-C, intermediate-density lipoprotein-cholesterol; LDL, low-density lipoprotein; VLDL, very-low-density lipoprotein.
*p Value represents the between-group treatment effect from mixed-model repeated-measures analysis of weeks 0–48.
†Sample size indicates the number of subjects remaining at each evaluation.